(Q51506989)

6 April 2018

title

Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. (English)

1 reference

6 April 2018

1 reference

2

1 reference

6 April 2018

Niels Obel

3

object named as

Obel N

1 reference

6 April 2018

Hansen AB

1

1 reference

6 April 2018

Andersen O

4

1 reference

6 April 2018

Nielsen H

5

1 reference

6 April 2018

Gerstoft J

6

1 reference

6 April 2018

publication date

1 January 2006

1 reference

6 April 2018

published in

HIV Medicine

1 reference

6 April 2018

volume

7

1 reference

6 April 2018

issue

1

1 reference

6 April 2018

page(s)

38-45

1 reference

6 April 2018

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Body composition changes in 308 Norwegian HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00334.X

10.1111/J.1468-1293.2005.00334.X

21 January 2018

Identifiers

DOI

1 reference

6 April 2018

PubMed ID

16313291

1 reference

6 April 2018